Born from a personal journey, our mission is to transform the landscape of rare disease treatment, inspired by patients, their families, and the unwavering support of a dedicated community.
The principle of “Do No Harm,” rooted in medical ethics, prioritizes safety and minimizes risk. At Bina Therapeutics, this value drives our commitment to safer, more effective treatments through advanced delivery methods and careful screening to reduce toxicity and protect patient well-being.
Starting with Pseudomyxoma Peritonei, We’re attempting to break the boundaries of translational drug discovery from pre-clinical to patient in record time. We aim to frequently update you on our progress, sharing every interaction associated with a positive step towards realizing our goal.
Starting with Pseudomyxoma Peritonei our plan is to find more effective treatment strategies for rare diseases. In order to achieve this we connect with leading, well-known researchers in each disease cohort to share our work for input throughout all stages from hypothesis to production ensuring no stone is unturned.
Our Scientific collaborators represent a powerhouse of expertise, guiding our work with invaluable advice and insights. Their dedication and support have been instrumental in shaping our progress, and we deeply appreciate their ongoing contributions to advancing our mission.
We’re in pursuit of a goal that aims to help thousands of people who are suffering from rare diseases starting with Pseudomyxoma Peritonei. Follow our story with frequent updates documenting all of our milestones and outcomes.
